United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
GAITHERSBURG, Md., Dec. 08, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that management will participate in the Guggenheim Securities 3rd Annual Boston Healthcare Conference.
Conference details are as follows:
Date: Tuesday, December 15, 2015
Forum: One-on-one meetings
Location: The Langham Boston, Boston, MA
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company’s website, novavax.com.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Senior Manager, Investor Relations [email protected] 240-268-2000 Russo Partners, LLC David Schull Todd Davenport, Ph.D. [email protected] [email protected] 212-845-4271
